$SIBN

FRANCIS LAURA sold $1.1M of SIBN (indirect holdings)

FRANCIS LAURA (Chief Executive Officer) sold 55,807 indirectly-held shares of SI-BONE, Inc. (SIBN) at an average of $19.50 ($19.46–$20.02, $1.09M total) across 2 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FRANCIS LAURA
Published Aug 21, 2026, 9:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate market impact.

02

Market read

Insider sell adds to routine monitoring data; unlikely to drive significant price movement.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

CEO Laura Francis sold 55,807 shares for $1.09M via a 10b5‑1 plan, reducing her stake to 317,463 shares.

Expected impact

Minor downward pressure, likely within normal volatility range.

Evidence & confidence

Sale size is modest relative to float and disclosed under a pre‑arranged plan, reducing informational value.

Market effects

Minimal impact on orthopedic device sector; no broader industry signal.

No regional effect; company is US‑based with limited market exposure.

Negligible global relevance.

Counterpoint

The sale could be a routine liquidity move, not a negative signal; price may remain stable.

Key entities

  • Laura Francis

    Chief Executive Officer of SI‑BONE, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

SI-BONE, Inc. (SIBN): Results of Operations and Financial Condition

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t